厄洛替尼联合化疗治疗进展期胰腺癌的疗效观察

目的:观察厄洛替尼联合化疗治疗进展期胰腺癌的疗效和不良反应。方法:吉西他滨(健择)1.0g/m2,静滴,d1,d8;厄洛替尼100mg,1次/日,每3周重复。结果:18例患者均可评价,获得CR0例,PR5例,SD8例,PD5例,有效率(RR)27.7%,总的疾病控制率(DCR)72.2%;中位肿瘤进展时间4.2个月,平均总生存期9.6个月。主要不良反应为胃肠道反应、骨髓抑制、皮疹。Ⅲ～Ⅳ度腹泻发生率11.1%(2/18)。Ⅲ～Ⅳ度中性粒细胞减少发生率44.4%(8/18)。Ⅲ～Ⅳ度血小板减少发生率27.7%(5/18)。结论:厄洛替尼联合吉西他滨治疗进展期胰腺癌有效,不良反应可耐受。

Objective:Observation of erlotinib combined with chemotherapy in treatment of advanced pancreatic cancer curative effect and adverse reaction.Methods:Introduction of gemcitabine 1.0g/m2,intravenous infusion,d1,d8,erlotinib 100mg qd,each cycle was 3 weeks.Results:18 patients could be evaluated for efficacy.0 cases achieved CR.5 cases achieved PR.8 cases was SD.5 cases was PD.RR was 27.7%.Overall disease control rate(DCR) was 72.2%;in tumor progression timewas 4.2 months,median overall survival at 9.6 months.The mainly poisonous deputy reaction were gastrointestinal reaction、yelosuppression and rash.Grade Ⅲ～Ⅳ toxicities included diarrhea(11.1%,2/18),neutropenia(44.4%,8/18)and thrombocytopenia(27.7% ,5/18).Conclusion:The erlotinib combined with chemotherapy is well effective for patients in the treatment of advanced pancreatic cancer,toxicity can be tolerated.